Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.schres.2008.09.031. Epub 2008 Nov 6.
Affiliations
- PMID: 18993031
- DOI: 10.1016/j.schres.2008.09.031
Randomized Controlled Trial
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial
Robert A Rosenheck et al. Schizophr Res. 2009 Jan.
Abstract
Purpose: Previous analysis of data from CATIE showed that patients randomly assigned to switch to a new medication were more likely to discontinue study drug than those who stayed on the medication they had been taking prior to randomization. This study addresses additional outcomes measures evaluating symptoms, neurocognition, quality of life, neurological side effects, weight, and health costs. First, considering patients randomized to olanzapine or risperidone, outcomes among patients who had been on the drug to which they were randomized prior to CATIE (N=129 "stayers") were compared to outcomes of those who switched to either of these two drugs (N=269 "switchers"). A second set of analyses considered patients on baseline monotherapy with olanzapine (N=297); risperidone (N=252) or quetiapine (n=87) and compared those randomly assigned to stay on each of these medications with those assigned to switch to any of the other five phase 1 medications in CATIE. In mixed models of each outcome the independent variable of primary interest represented stay vs. switch, with multivariate adjustment for potential confounding factors.
Results: With one exception, there were no significant differences between stayers and switchers on any outcome measure in either set of analyses. The exception was that, in the second set of analyses, patients who stayed on olanzapine showed greater weight gain than those who switched from olanzapine to other drugs.
Conclusion: Switching to a new medication yielded no advantage over staying on the previous medication. Staying on olanzapine was associated with greater weight gain.
Similar articles
- Effectiveness of switching antipsychotic medications.
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Essock SM, et al. Am J Psychiatry. 2006 Dec;163(12):2090-5. doi: 10.1176/ajp.2006.163.12.2090. Am J Psychiatry. 2006. PMID: 17151159 Clinical Trial. - What CATIE found: results from the schizophrenia trial.
Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA. Swartz MS, et al. Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/ps.2008.59.5.500. Psychiatr Serv. 2008. PMID: 18451005 Free PMC article. Clinical Trial. - Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Mladsi DM, et al. Curr Med Res Opin. 2004 Dec;20(12):1883-93. doi: 10.1185/030079904X11510. Curr Med Res Opin. 2004. PMID: 15701206 - Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.
Hargreaves WA, Gibson PJ. Hargreaves WA, et al. CNS Drugs. 2005;19(5):393-410. doi: 10.2165/00023210-200519050-00003. CNS Drugs. 2005. PMID: 15907151 Review. - Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Asmal L, et al. Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Cochrane Database Syst Rev. 2013. PMID: 24249315 Review.
Cited by
- Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ. Faries D, et al. BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142. BMC Med Res Methodol. 2012. PMID: 22974273 Free PMC article. Clinical Trial. - The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthøj B, Leboyer M, Leweke FM, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE. Leucht S, et al. Schizophr Bull. 2015 May;41(3):549-58. doi: 10.1093/schbul/sbv019. Epub 2015 Mar 18. Schizophr Bull. 2015. PMID: 25786408 Free PMC article. Review. - Predictors of antipsychotics switching among ambulatory patients with schizophrenia in Ethiopia: a multicenter hospital-based cross-sectional study.
Kiflu M, Azale T, Gubae K, Agegnew Wondm S, Mebratu E, EliasErgena A, Abubeker O, Mekonnen GA. Kiflu M, et al. Ann Gen Psychiatry. 2024 Jan 3;23(1):2. doi: 10.1186/s12991-023-00472-z. Ann Gen Psychiatry. 2024. PMID: 38172853 Free PMC article. - Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes.
Khandker R, Shepherd J, Chekani F, Qureshi Z, Bailey H, Berry M, Wright J, Massey L. Khandker R, et al. Neuropsychiatr Dis Treat. 2022 May 18;18:1057-1067. doi: 10.2147/NDT.S358392. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 35611118 Free PMC article. - American Diabetes Association Postgraduate Meetings--2011.
Bloomgarden ZT. Bloomgarden ZT. Diabetes Care. 2011 Nov;34(11):e164-9. doi: 10.2337/dc11-1557. Diabetes Care. 2011. PMID: 22025788 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical